SIRIS-Lab/unlabelled-sti-corpus huggingface dataset:
Spatial fractionation of the dose in proton therapy: a novel therapeutic approach

Radiotherapy (RT) is one of the most frequently used methods for cancer treatment (above 50% of patients will receive RT). Despite remarkable advancements, the dose tolerances of normal tissues continue to be the main limitation in RT. Finding novel approaches that allow increasing normal tissue resistance is of utmost importance. This would make it possible to escalate tumour dose, resulting in an improvement in cure rate. With this aim, I propose a new approach, called proton minibeam radiation therapy (PROTONMBRT), which combines the prominent advantages of protons for RT and the remarkable tissue preservation provided by the use of submillimetric field sizes and a spatial fractionation of the dose, as in minibeam radiation therapy (MBRT). The main objectives of this project are to explore the gain of therapeutic index for radioresistant tumors, to disentangle the biological mechanisms involved and to evaluate the clinical potential of this novel approach. For this purpose, a method for minibeam generation adequate for patient treatments and a complete set of dosimetric tools will be developed. Then, tumour control effectiveness will be evaluated, and the possible biological mechanisms involved both in tumour and normal tissue responses will be disentangled. The gain in normal tissue recovery can foster one of the main applications of proton therapy, paediatric oncology, as well as open the door to an effective treatment of very radioresistant tumours, such as high-grade gliomas, which are currently mostly treated palliatively.
Opportunity to carry european autonomous driving further with fdsoi technology up to 12nm node

OCEAN12 targets the key societal challenge of smart mobility. Based on the innovative FDSOI technology, OCEAN12 will develop new processors and applications design that leverage Fully Depleted Silicon On Insulator (FD-SOI) technology to offer the industry’s lowest power consuming processor, especially for automotive and aeronautic applications.
OCEAN12 will develop a technology platform benefitting from FDSOI design’s extreme low leakage and operating voltage (Vdd)  scalability attained thank to reverse and forward body biasing (RBB/FBB) of the integrate circuit and it power system architecture. This high performance, low power solution will enable the next strategic generations of smart vehicles. This platform will rely on:
• pilot line facilities capable to manufacture advanced substrates compatible with 12FDX technology and define pathfinding solutions to push 12FDX technology performances and develop innovative sensors,
• development of innovative designs to enhance FDSOI capacity and guarantee the highest level of integrated solutions,
• the manufacturing of high performance ICs using all panel of FDSOI technologies,
The produced highly integrated, reliable, ultra low power and lower cost components will be integrated in complex embedded systems accessible to TIER-1, 2 and OEMs and answering strategic challenges of future vehicles generations. Several product demonstrators are targeted: high end microcontroller plug and play board, high performance sensors data fusion, highly integrated low power video processing, awaking systems.
A strong added value network is created across this project to enhance a competitive European value chain on a European breakthrough and secure a unique FDSOI roadmap beyond the 22FDX. 
OCEAN 12 finally highlights Europe’s unique leading position on FDSOI technology integrating the entire manufacturing chain in this dynamic, from substrate suppliers and foundries to TIER-1 and OEM, including academia and RTO’s.
Providing the right care to the right patient with myelodysplastic syndrome at the right time

Myelodysplastic syndromes (MDS) are chronic bone marrow malignancies of the elderly, complicated by severe anaemia. MDS significantly affects quality-adjusted survival and it imposes an increasing financial burden on patients and healthcare (HC) systems. The burden of disease is expected to worsen in the future, given the aging EU population and newly identified MDS cases among those diagnosed with ‘Anaemia of the Elderly’. EUMDS - a unique registry with prospective, observational data on 1600 lower-risk MDS patients from 16 EU countries - enables comparison of existing MDS HC interventions (HCI).
Objectives
1) Comparison of outcomes and costs of existing HCI, using established and new core outcome sets. This, alongside health technology assessment, will provide robust evidence to underpin sustainable use of HC resources;
2) Enhanced compliance with diagnostic procedures in MDS by introducing new minimally-invasive diagnostic methods. This will increase the number of correctly and timely diagnosed MDS patients;
3) Raised awareness of the relevance of obtaining the right diagnosis in elderly by comparing HRQoL between EUMDS and against a non-MDS cohort. This will improve HRQoL of individual patients through better tailoring of HCI;
4) Better outcome predictability of available HCI by refining classification of cases using molecular characterisation to incorporate response to HCI and to provide evidence for personalised medicine;
5) Improved, evidence-based, guidelines supporting the regulatory process, and providing information to patients and physicians to promote personalised decisions in MDS care;
6) Establishment of a European MDS competence network encompassing all stakeholders in the MDS field.
Relevance
Better treatment compliance, a more evidence-based use of HCI and an increasing tailored use of existing HC options will contribute to an efficient and cost effective (personalised) use of HC resources for elderly patients with MDS and their co-morbidities.
Mediterranean Transnational Technology Transfer

Among the difficulties faced by most Technology Transfer Offices (TTOs) and Research & Technology Organisations (RTOs) in MED and elsewhere is that of building effective Research-Industry partnerships. Technology transfer involves the processes of capturing and sharing explicit and tacit knowledge and includes both commercial and non- commercial activities. In particular, EU has identified the transnational dimension of technology transfer as one of ten key areas for action on its Innovation Strategy based on the lack of interegional cooperations and joint approaches. The LP, National Hellenic Research Foundation, has identified partners of high caliber sharing experiences, tools and moreover the vision on setting such a Transnational Technology Transfer (TTT) initiative. The project brings together seven regions (Attiki, Voreio Aigaio, Provence- Alpes-Côte d’Azur, Puglia, Murcia, Andalucía and Crete) from France, Italy, Spain and Greece with a variety of profiles but common needs and perspectives on improving TTT methods and assisting regional stakeholders to develop strategic partnerships. The project will deliver a network on Technology Transfer targeted to MED needs and accommodate profiles ranging from the “blue chip coast” PACA to “low tech” Voreio Aigaio. MET3 aims to develop a modular toolbox for integrated TTT and thus facilitate exploitation of research results by taking into account technology and other “soft” aspects of the process.
Le cas Valentin Krivič

Abstract The aim of this paper is to define the specific, culturally meaningful situation of the not very well-known poet Valentin Annenskii-Krivich (1880–1936), the son of Innokentii Annenskii. Krivichʼs poetry can be studied for its “individual poetic style of a little-known author”, but also for questions such as celebrity and obscurity, the role of family relationship, literary heritage, originality and imitation. The article concentrates on the composition, motifs and stylistic devices of Krivichʼs anthology Flowers and Grass ( Tsvetotravy , 1912). The analysis of the poem ‘From there’ (‘Ottuda’) reveals that deliberate and explicit imitation of Annenskii allowed Krivich to create one of his best and most original works.
Reconstitution of Adiposome and Artificial Lipid Droplets

The Lipid droplet (LD) is a cellular organelle that consists of a neutral lipid core with a phospholipid monolayer membrane associated with proteins. The presence of this organelle in organisms ranging from bacteria to humans demonstrates that it is highly conserved and may be the first membrane-bound organelle in living organisms. Recent progress in LD research demonstrates its important roles in energy homeostasis and metabolic syndromes. However, the mechanisms governing its formation, dynamics, interaction with other cellular organelles, and association with proteins have remained elusive. Therefore, we developed an in vitro system to facilitate the elucidation of these mechanisms, based on the reconstitution of artificial LDs. First, we generated sphere-shaped structures with a neutral lipid core and phospholipid monolayer membrane by mechanically mixing neutral lipids and phospholipids followed by two-step purification. Since the artificial lipid vesicle, a double layer phospholipid membrane structure, is termed as “liposome”, we named this monolayer phospholipid membrane-bound structure “adiposome”. We then recruited LD structure-like/resident proteins to the adiposome, including the bacterial LD protein MLDS, C. elegans LD protein MDT-28, or mammalian LD protein ADRP/PLIN2. We term the functional protein-coated adiposomes, “artificial lipid droplets”. Using this experimental system, different proteins can be recruited to build artificial LDs for myriad biological and medical goals.
LUMINAIRE

The luminaire for tubular lamps has a housing (1) having a light emission plane (2) and several lighting units (10) accommodated in the housing. Each unit (10) has a pair of opposed side reflectors (12), which are possibly connected to lamellae (15) and which bound the light emission window (11) of the unit. Between two adjacent units (10) a possibly light transmitting, e.g. perforated, plate (20) is present, which fills the light emission plane (2). The plate (20), the side reflectors (12) and the lamellae (15) may constitute an assembly.
Advanced automated process for low cost efficient custom mosaic manufacturing

MOSART aims to bring to full industrialization and commercialization a proprietary advanced manufacturing system for high quality custom-made mosaics. Europe accounts for 30% global tile production and 26% consumption market share. Europe is recognized worldwide for innovative designs and concepts but high manufacturing costs have begun to deplete the design and art industry. The quality of mosaics have diminished immensely and jobs have been removed from Europe and outsourced to India and China. Artaic strives to resolve these issues and position European design innovation as a leader on a global stage, while returning jobs back to Europe, fostering creativity and stimulating the European art and construction market.
Today the process stages of mosaic artwork from design through installation are complicated and expensive with long lead times due to manual fabrication and lengthy supply chains. Artaic’s state of the art patent-pending robotic technology and CAD mass-customization software allow to automate production and assembly of large scale, high volume affordable custom-made mosaics with unparalleled speed, efficiency, flexibility, and cost savings. First generation robotic pilot production line proved to be 10x faster than the traditional method and the prototyped second generation robot, called ""TileJet"", adds more speed (100-200x) and productivity together with accuracy and flexibility. Such a technology has reached now a TRL of 8.
MOSART Phase 1 project aims at establishing a robust industrialization and operational plan, at assessing the feasibility of a customer-centred web portal enabling direct B2C sales, identifying all stakeholders in the value chain securing appropriate sale channels and strategic partnerships and at strengthening the business model through an in-depth analysis of customer segments and financial projections.
In situ structural analysis of nuclear pore complex assembly intermediates by cryo-fib-tomography

Nuclear pore complexes (NPCs) are fundamental supra-molecular complexes mediating the molecular traffic between nucleus and cytoplasm. They consist of over 1000 proteins that need to be assembled in a coordinated manner each cell division. Recent structural work has elucidated a considerable part of the NPC architecture, however how the NPC scaffold is assembled remains poorly understood on the structural and mechanistic level. 
Here I propose for the first time to arrest and structurally analyze NPC assembly intermediates. The proposed research aims to enrich the intermediates in genetically modified yeast using an anchor away approach. Subsequently the state-of-the-art Focused-Ion-Beam specimen thinning technology will be combined with cryo Electron-Tomography to examine the intermediates in their native context. 
The structures of the assembly intermediates will fundamentally advance our understanding of the NPC assembly mechanism that has been strongly implicated in cancerogenesis and various degenerative diseases. The proposed research thus holds great promise to enable the development of novel therapeutic compounds.
This project will complement on my strength in using cryo Electron-Microscopy and expand it to in cell studies, hence providing me full professional independence. The supervisor Dr. Beck is very experienced in NPC structure research. EMBL is a well-established host institution and will provide me excellent training and infrastructure to conduct the proposed research. These two factors together constitute a robust basis to reach the goals of the proposal.
Produced data will be made publicly available and dissemination of the results in conferences and to a broader audience is an integrated part of the application.
In perspective the implementation of this exclusive method will allow investigating other large macromolecular complexes and their assembly paths in situ providing an appealing strategy for the European scientific community.
Modeling the spatial distribution of Chagas disease vectors using environmental variables and people´s knowledge

Abstract Background Chagas disease is caused by the protozoan Trypanosoma cruzi, which is transmitted to mammal hosts by triatomine insect vectors. The goal of this study was to model the spatial distribution of triatomine species in an endemic area. Methods Vector’s locations were obtained with a rural householders’ survey. This information was combined with environmental data obtained from remote sensors, land use maps and topographic SRTM data, using the machine learning algorithm Random Forests to model species distribution. We analysed the combination of variables on three scales: 10 km, 5 km and 2.5 km cell size grids. Results The best estimation, explaining 46.2% of the triatomines spatial distribution, was obtained for 5 km of spatial resolution. Presence probability distribution increases from central Chile towards the north, tending to cover the central-coastal region and avoiding areas of the Andes range. Conclusions The methodology presented here was useful to model the distribution of triatomines in an endemic area; it is best explained using 5 km of spatial resolution, and their presence increases in the northern part of the study area. This study’s methodology can be replicated in other countries with Chagas disease or other vectorial transmitted diseases, and be used to locate high risk areas and to optimize resource allocation, for prevention and control of vectorial diseases.
PROCESS FOR APPLYING A POLYURETHANE DISPERSION BASED FOAM TO AN ARTICLE

Disclosed is a process for making a two or more component foam composite obtained by adhesion of a polyurethane foam onto a substrate comprising the steps of frothing an aqueous polyurethane formulation; applying the froth to a substrate and drying the froth into a foam wherein the foam has a dry density of 35 kg/m<3> to 160 kg/m<3> (2.2-10 Ibs/cft). The process allows the production of foam backed textiles without the need for a flame lamination step or the need for an adhesive layer between the textile and the foam layer and is optionally optimized for superior handling properties for covering polyurethane molded foam cushions.
IDF21-0334 Bibliometric analysis on telehealth for people with diabetic foot based on Web of Science

Background: The COVID-19 pandemic necessitated dramatic changes in the healthcare delivery to diabetic foot people requiring technologic solutions. Aim: To analyze the current status and trends of scientific publications on telehealth for people with diabetic foot in Web of Science (WoS). Method: A bibliometric-type methodology was used. Data were obtained from the WoS Core Collection in July 2021. Publication were identified using relevant search terms (“diabetic”, “tele*”, “Foot ulcer*”). There was no limitation of language considering that study seeks to present a global historical panorama. VOSviewer Software was used to analyze standard bibliometric data on the number of publications, journals, authors, countries, institutions, collaborations and keywords. Results: A total of 65 documents were retrieved from 2003 to 2020. The number of publications on the subject showed a steadily increase from 2003 to 2020, with a sudden peak in 2020 which reached 14 accounting for 21,5% of the total. The top 3 most active journals and authors and the most cited ones are shown in Table 1. The three countries that published the most were the United States of America (15), followed by Denmark (9) and Norway (7). The countries with the most citations were the United States of America (168), Denmark (135) and Netherlands (130). The top 3 most cited institutions were University of Amsterdam (130), Ziekenhuis Groep Twente (110) and Stavanger University Hospital (96). We identified 5 clusters connected by the authors Armstrong D.G, Van Netten J.J and Bus S. The four most frequently used keywords were “telemedicine” (29), care (13), “diabetic foot” (12) and “telehealth” (11).Tabled 1VariablesNJournals that published the mostJournal of Telemedicine and Telecare4Diabetes Technology & TherapeuticsDiabetes care44Most cited JournalsJournal of Telemedicine and Telecare69Diabetes Technology Therapeutics63Diabetes Care57Authors who published the mostIversen, MM7Bus, SA6Graue, M6Most cited authorsBus, SA130Van Netten, JJ113Iversen, MM96 Open table in a new tab Discussion: The findings from this bibliometric study showed that telehealth technologies are an emerging area in clinical research publications as a strategy for the continuity of care for diabetic foot people. Since 2003, an increasing number of publications were identified on WoS, mainly in 2020, possibly related to the need for new approaches and healthcare delivery due to the COVID-19 pandemic.
Enhanced Cu(II) rejection and fouling reduction through fabrication of PEG-PES nanocomposite ultrafiltration membrane with PEG-coated cobalt doped iron oxide nanoparticle

Membrane modified by adding nanoparticles coined as nanomodified membrane is another latest trend in membrane technology. This paper investigates the influence of polyethylene glycol (PEG) coated cobalt doped iron oxide (Co-Fe2O3) nanoparticles on the morphological and properties of (PES) ultrafiltration membrane (UF). The synthesized Co-Fe2O3 nanoparticles were coated with different concentrations of PEG solutions to prevent them from agglomeration and then added to the PES/DMF dope solutions. The performance of the nanomodified membranes was then compared to the control PEG/PES/DMF dope solutions in terms of flux rates and Cu(II) removal at various operating conditions. The antifouling properties were determined using bovine serum albumin (BSA) as the model foulant. Findings revealed that the Cu(II) removal efficiency of the nanomodified membranes was enhanced considerably (as high as 96%) and the antifouling properties improved. In order to obtain membranes with high Cu(II) removal and reasonable flux rates the concentration of nanoparticles must be kept at 6% but PEG coating concentration high (6-9%); with ratio of PEG coating to Co-Fe2O3 kept more than 1.0. (C) 2014 Taiwan Institute of Chemical Engineers.
Extensible processing units (xpus) as enablers of the high-performance low-power embedded market

According to Frost & Sullivan (2017),  https://store.frost.com/global-autonomous-driving-market-outlook-2018.html,  in 2024 there will be in Europe more than 1.5 million cars which will have at least conditional automation with each car requiring an average of about 2000€ in chips to enable automatic driving. Thus the total available market in Europe will reach 3000M€ in 5 years with a robust CAGR of 30%. Markets in USA and China will be of similar size.
The requirements for Level 5 autonomous cars (fully-autonomous vehicles with performance equal to that of a human driver in every driving scenario including extreme environments) will require substantially high processing power not currently available with today’s microprocessors. Processors in future cars not only must deliver increasing higher computing power but also they must do so as efficiently (low-power) as possible given strict automotive safely constraints.  Furthermore, fully-autonomous cars require robust real-time features and dynamic balance between safety, performance and power. In contrast, current microprocessors are either high-performance but are not power efficient (e.g., Intel), or are low-power but unable to reach top performance (e.g., ARM), and generally do not have a strong real-time capability. These key bottlenecks are hindering advances towards fully automated vehicles. MOSAIK has defined a novel modular architecture designed from the ground-up to solve these urgent challenges. 
To keep European Industry leadership (https://www.mckinsey.com/industries/automotive-and-assembly/our-insights/a-long-term-vision-for-the-european-automotive-industry) setting the framework for car connectivity and user experience is a must. And to do so European industry needs a European Semiconductor company able to reach very high-performance at low power and provide the balance between performance, security and power consumption the industry is asking for.
EIN INNOVATIONSPROJEKT, DAS AUS DEM ERWERB EINES NEUEN LASERTHERAPIEGERÄTS BESTEHT UND AUF DIE ENTWICKLUNG DER BERUFLICHEN TÄTIGKEIT DES PHYSIOTHERAPEUTEN UND DIE VERBESSERUNG DER WETTBEWERBSPOSITIONIERUNG ABZIELT.

RICCARDO TURONI UND EIN PHYSIOTHERAPEUT, DER 19 JAHRE LANG IN FORLI UND ROMAGNA, FREIBERUFLICH TÄTIG, IM SEPARATEN MANAGEMENT INPS EINGESCHRIEBEN IST. MIT DEM HIER VORGESTELLTEN PROJEKT ZIELT ES DARAUF AB, SEINE BERUFLICHE TÄTIGKEIT ZU ENTWICKELN UND ZU STÄRKEN, DAS QUALITÄTSNIVEAU DER ERBRACHTEN DIENSTLEISTUNGEN ZU ERHÖHEN, SEINE WETTBEWERBSPOSITIONIERUNG ZU VERBESSERN, DAS MANAGEMENT UND DIE EFFIZIENZ DER AKTIVITÄT SELBST ZU VERBESSERN. UM DIESE ZIELE ZU ERREICHEN, HAT ER DIE INVESTITION IN EIN NEUES LASERTHERAPIEGERÄT DER NEUESTEN GENERATION GEPLANT, DAS TIEFE KONTUSIVE UND VERZERRENDE TRAUMATA UND ANDERE ARTEN VON PATHOLOGIEN BEHANDELN KANN. DIE DURCH DIE REALISIERUNG DIESES PROJEKTS ERWARTETEN ERGEBNISSE SIND SOWOHL EINE STEIGERUNG DER KUNDEN UND BEHANDLUNGEN ALS AUCH EINE STEIGERUNG DES UMSATZES SOWIE EINE REDUZIERUNG DER LEISTUNGSZEITEN UND DAMIT EINE VERBESSERUNG DER EFFIZIENZ.